Steven Cohen (Trades, Portfolio), through Point72 Asset Management, has recently made a notable adjustment in the firm's investment portfolio by reducing its stake in Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). This trade has altered the firm's portfolio by a -0.09% impact, with CRNX now representing 0.36% of the total portfolio and 5.10% of the firm's holdings in the traded stock.